Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Broadstock M, Ballard C, Corbett A.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):779-86. doi: 10.1586/17512433.2014.966814. Epub 2014 Oct 10.

PMID:
25301532
[PubMed - in process]
2.

Treating psychosis in movement disorder patients: a review.

Borek LL, Friedman JH.

Expert Opin Pharmacother. 2014 Aug;15(11):1553-64. doi: 10.1517/14656566.2014.918955. Epub 2014 May 20.

PMID:
24846479
[PubMed - in process]
3.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.

Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30.

PMID:
24682754
[PubMed - in process]
Free PMC Article
4.

Treatment of psychosis and dementia in Parkinson's disease.

Goldman JG, Holden S.

Curr Treat Options Neurol. 2014 Mar;16(3):281. doi: 10.1007/s11940-013-0281-2.

PMID:
24464490
[PubMed]
5.

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.

Meltzer HY, Roth BL.

J Clin Invest. 2013 Dec 2;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review.

PMID:
24292660
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.

Kingwell K.

Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.233. Epub 2013 Nov 19. No abstract available.

PMID:
24247322
[PubMed - indexed for MEDLINE]
7.

Pimavanserin as treatment for Parkinson's disease psychosis.

Fox SH.

Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1. No abstract available.

PMID:
24183566
[PubMed - indexed for MEDLINE]
8.

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.

Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28.

PMID:
24183563
[PubMed - indexed for MEDLINE]
9.

Pimavanserin for the treatment of Parkinson's disease psychosis.

Friedman JH.

Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345. Review.

PMID:
24016069
[PubMed - indexed for MEDLINE]
10.

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.

Hubbard D, Hacksell U, McFarland K.

Behav Pharmacol. 2013 Aug 21. [Epub ahead of print]

PMID:
23969614
[PubMed - as supplied by publisher]
11.

Is there room for non-dopaminergic treatment in Parkinson disease?

Lieberman A, Krishnamurthi N.

J Neural Transm. 2013 Feb;120(2):347-8. doi: 10.1007/s00702-012-0946-0. Epub 2012 Dec 16.

PMID:
23242741
[PubMed - indexed for MEDLINE]
12.

Is there room for new non-dopaminergic treatments in Parkinson's disease?

Pilleri M, Koutsikos K, Antonini A.

J Neural Transm. 2013 Feb;120(2):349-52. doi: 10.1007/s00702-012-0947-z. Epub 2012 Dec 11.

PMID:
23229903
[PubMed - indexed for MEDLINE]
13.

Inverse agonism and its therapeutic significance.

Khilnani G, Khilnani AK.

Indian J Pharmacol. 2011 Sep;43(5):492-501. doi: 10.4103/0253-7613.84947.

PMID:
22021988
[PubMed]
Free PMC Article
14.

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.

McFarland K, Price DL, Bonhaus DW.

Behav Pharmacol. 2011 Oct;22(7):681-92. doi: 10.1097/FBP.0b013e32834aff98.

PMID:
21921840
[PubMed - indexed for MEDLINE]
15.

Parkinson's disease dementia.

Docherty MJ, Burn DJ.

Curr Neurol Neurosci Rep. 2010 Jul;10(4):292-8. doi: 10.1007/s11910-010-0113-7. Review.

PMID:
20428976
[PubMed - indexed for MEDLINE]
16.

Hallucinations and psychosis in Parkinson's disease.

Rabey JM.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S105-10. doi: 10.1016/S1353-8020(09)70846-6. Review.

PMID:
20123547
[PubMed - indexed for MEDLINE]
17.

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH.

Neuropsychopharmacology. 2010 Mar;35(4):881-92. doi: 10.1038/npp.2009.176. Epub 2009 Nov 11.

PMID:
19907417
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.

Abbas A, Roth BL.

Expert Opin Pharmacother. 2008 Dec;9(18):3251-9. doi: 10.1517/14656560802532707 . Review.

PMID:
19040345
[PubMed - indexed for MEDLINE]
19.

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.

Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010.

PMID:
18534670
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

ACP-103, a 5-HT2A receptor inverse agonist.

Roberts C.

Curr Opin Investig Drugs. 2006 Jul;7(7):653-60. Review.

PMID:
16869120
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk